BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Korean startup Seegene inks supply deal of 4 M COVID-19 tests with Brazil

February 11, 2022 | News

To deliver 'AllplexÃ¢â??Â¢ SARS-CoV-2/FluA/FluB/RSV,' the optimized test for 'twindemic' with its capability to distinguish between COVID-19 and Flu A/B



Seegene Inc, South Korea's molecular diagnostic startup, has announced that it has signed a supply deal with the Ministry of Health of Brazil to deliver four million COVID-19 tests.

Since January 2022, Brazil has battled a 'twindemic,' a rapid surge in both Flu A and COVID-19 infections due to the rapid spread of the Omicron variant. More seriously, new daily cases of COVID-19 have recently exceeded 280,000 cases, which is the highest figure since the first outbreak of the pandemic. While the country has been seeking to accelerate its quarantine efforts, there is a growing demand for COVID-19 tests as well.

In response, Seegene will deliver a shipment of four million Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay, capable of identifying respiratory viruses including COVID-19, Flu A/B as well as RSV in a single test. This assay is expected to be the optimized solution in Brazil where they are experiencing a rapid surge in both COVID-19 and Flu A cases.